The results of a major clinical trial were recently published in the New England Journal of Medicine. The study was conducted to evaluate the efficacy of Empagliflozin (Jardiance) in patients with broad-range of chronic kidney disease (CKD) – irrespective of diabetes diagnosis.
About 7,000 patients were randomly assigned to receive Jardiance 10 mg daily or placebo. The primary outcome was a combination of progression of CKD or mortality from cardiovascular causes after 2 years of follow up.
The results of the trial were published in January 2023 and showed that Jardiance significantly reduced the risk of progression of CKD or cardiovascular mortality, as well as all-cause hospitalization compared to placebo.
- The benefits were observed in patients with a wide-range of CKD severity, including those with an eGFR 20-45, or who had an eGFR 45-90 but with microalbuminuria >200.
The safety profile of Jardiance was generally favorable. The most common adverse events were hypoglycemia, UTI, and genital infections.
Overall, the results of this trial suggest that Jardiance is an effective and well-tolerated treatment for patients with chronic kidney disease from various causes.
Dr. Tashko